Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

1001180-45-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1-Piperazinecarboxylic acid, 4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-, 1,1-dimethylethyl ester

    Cas No: 1001180-45-5

  • No Data

  • No Data

  • 1-100 Metric Ton/Day

  • Contact Supplier

1001180-45-5 Usage

Molecular weight

340.41 g/mol


1-Piperazinecarboxylic acid, 4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-, 1,1-dimethylethyl ester

Biological role

Antagonist of the serotonin receptor 5-HT2A

Medical uses

Treatment of hypertension and migraines


Selective antagonist of the serotonin receptor

Therapeutic potential

Studied for potential applications in various neurological and psychiatric disorders

Anti-cancer properties

Investigated for potential anti-cancer properties.

Check Digit Verification of cas no

The CAS Registry Mumber 1001180-45-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,1,1,8 and 0 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1001180-45:
65 % 10 = 5
So 1001180-45-5 is a valid CAS Registry Number.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017


1.1 GHS Product identifier

Product name (2R)-2-(4-chloro-3-fluorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-[(4-methoxycyclohexyl)amino]propan-1-one

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1001180-45-5 SDS

1001180-45-5Relevant articles and documents

Asymmetric Synthesis of Akt Kinase Inhibitor Ipatasertib

Han, Chong,Savage, Scott,Al-Sayah, Mohammad,Yajima, Herbert,Remarchuk, Travis,Reents, Reinhard,Wirz, Beat,Iding, Hans,Bachmann, Stephan,Fantasia, Serena M.,Scalone, Michelangelo,Hell, André,Hidber, Pirmin,Gosselin, Francis

, p. 4806 - 4809 (2017/09/23)

A highly efficient asymmetric synthesis of the Akt kinase inhibitor ipatasertib (1) is reported. The bicyclic pyrimidine 2 starting material was prepared via a nitrilase biocatalytic resolution, halogen-metal exchange/anionic cyclization, and a highly dia



Paragraph 0070-0071, (2015/04/15)

The invention provides new processes for making and purifying salts of hydroxylated cyclopentapyrimidine compounds, which are useful as AKT inhibitors used in the treatment of diseases such as cancer, including the monohydrochloride salt of (S)-2-(4-chlor

Synthesis of Akt inhibitor ipatasertib. part 1. Route scouting and early process development of a challenging cyclopentylpyrimidine intermediate

Lane, Jonathan W.,Spencer, Keith L.,Shakya, Sagar R.,Kallan, Nicholas C.,Stengel, Peter J.,Remarchuk, Travis

supporting information, p. 1641 - 1651 (2015/02/02)

Herein, the route scouting and early process development of a key cyclopentylpyrimidine ketone intermediate toward the synthesis of Akt inhibitor Ipatasertib are described. Initial supplies of the intermediate were prepared through a method that commenced with the natural product (R)-(+)-pulegone and relied on the early construction of a methyl-substituted cyclopentyl ring system. The first process chemistry route, detailed herein, enabled the synthesis of the ketone on a hundred-gram scale, but it was not feasible for the requisite production of multikilogram quantities of this compound and necessitated the exploration of alternative strategies. Several new synthetic approaches were investigated towards the preparation of the cyclopentylpyrimidine ketone, in either racemic or chiral form, which resulted in the discovery of a more practical route that hinged on the initial preparation of a highly substituted dihydroxypyrimidine compound. The cyclopentane ring in the target was then constructed through a key carbonylative esterification and subsequent tandem Dieckmann cyclization-decarboxylation sequence that was demonstrated in a racemic synthesis. This proof-of-concept was later developed into an asymmetric synthesis of the cyclopentylpyrimidine ketone, which will be described in a subsequent paper, along with the synthesis of Ipatasertib.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 1001180-45-5